The Pathogenesis of B-cell Non-hodgkin Lymphoma Associated with HBV (hepatitis B Virus) Infection is Regulated by C-Myc/PD-L1 Signaling Pathway

Overview

Journal Glob Med Genet

Publisher Thieme

Date 2025 Feb 10

PMID 39925444

Authors

Yu Zhao

Jian Yang

Sai Xu

Ying Wang

Jian Bo

Affiliations

Soon will be listed here.

Abstract

Background: HBV is closely associated with the incidence of B-NHL (B-cell non-hodgkin lymphoma). This project intends to establish HBV infection-induced B-NHL cells and animal models to clarify the mutual mechanism of HBV infection and B-NHL pathogenesis.

Methods: The relationship between HBV and B-NHL was studied based on the HBV infection model, which included CTC cells and HBV transgenic mice. Moreover, differential expression analysis of transcriptome profiling was performed to confirm the mechanism.

Results: The HBsAg expression and HBV-DNA could be found in tumor tissues of HBV group, but negative in the control group. Moreover, there were clearly differences between the two groups in the transcriptome of tumor tissues and CTC. HBsAg significantly promoted lymphocytes associated with c-Myc and PD-L1.

Conclusion: The promoted effect induced by HBsAg in lymphocytes was associated with PD-L1 mediated by c-Myc.

References

Huang C, Yang Y, Chen Y, Chang J, Chen K, Lu C . The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. J Viral Hepat. 2017; 24(10):885-894. DOI: 10.1111/jvh.12713. View

Lai W, Huang B, Wang J, Lin P, Yang P . A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. Mol Ther Nucleic Acids. 2016; 5(12):e397. DOI: 10.1038/mtna.2016.102. View

Escors D, Gato-Canas M, Zuazo M, Arasanz H, Garcia-Granda M, Vera R . The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther. 2018; 3:26. PMC: 6160488. DOI: 10.1038/s41392-018-0022-9. View

Kuppers R . Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005; 5(4):251-62. DOI: 10.1038/nrc1589. View

Aceto N, Toner M, Maheswaran S, Haber D . En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition. Trends Cancer. 2017; 1(1):44-52. DOI: 10.1016/j.trecan.2015.07.006. View

Chisari F, Filippi P, McLachlan A, Milich D, Riggs M, Lee S . Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol. 1986; 60(3):880-7. PMC: 253312. DOI: 10.1128/JVI.60.3.880-887.1986. View

Li M, Gan Y, Fan C, Yuan H, Zhang X, Shen Y . Hepatitis B virus and risk of non-Hodgkin lymphoma: An updated meta-analysis of 58 studies. J Viral Hepat. 2018; 25(8):894-903. DOI: 10.1111/jvh.12892. View

Lemaitre M, Brice P, Frigeni M, Hermine O, Arcaini L, Thieblemont C . Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. J Infect. 2019; 80(2):219-224. DOI: 10.1016/j.jinf.2019.12.005. View

Shankland K, Armitage J, Hancock B . Non-Hodgkin lymphoma. Lancet. 2012; 380(9844):848-57. DOI: 10.1016/S0140-6736(12)60605-9. View

10.

Chiu B, Hou N . Epidemiology and etiology of non-hodgkin lymphoma. Cancer Treat Res. 2015; 165:1-25. DOI: 10.1007/978-3-319-13150-4_1. View

11.

Eichenauer D, Becker I, Monsef I, Chadwick N, De Sanctis V, Federico M . Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica. 2017; 102(10):1748-1757. PMC: 5622859. DOI: 10.3324/haematol.2017.167478. View

12.

Li M, Shen Y, Chen Y, Gao H, Zhou J, Wang Q . Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma. Int J Cancer. 2020; 147(8):2199-2209. DOI: 10.1002/ijc.33027. View

13.

Lun Y, Cheng J, Chi Q, Wang X, Gao M, Sun L . Transactivation of proto-oncogene c-Myc by hepatitis B virus transactivator MHBs. Oncol Lett. 2014; 8(2):803-808. PMC: 4081436. DOI: 10.3892/ol.2014.2190. View

14.

Zhou X, Wuchter P, Egerer G, Kriegsmann M, Kommoss F, Witzens-Harig M . Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin's lymphoma. Eur J Haematol. 2020; 104(5):469-475. DOI: 10.1111/ejh.13388. View

15.

Zhou X, Pan H, Yang P, Ye P, Cao H, Zhou H . Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma. BMC Cancer. 2019; 19(1):477. PMC: 6530193. DOI: 10.1186/s12885-019-5718-x. View

16.

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

17.

Chisari F, Filippi P, Buras J, McLachlan A, Popper H, Pinkert C . Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A. 1987; 84(19):6909-13. PMC: 299194. DOI: 10.1073/pnas.84.19.6909. View

18.

Tan P, He L, Xing C, Mao J, Yu X, Zhu M . Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development. J Clin Invest. 2019; 129(12):5261-5277. PMC: 6877338. DOI: 10.1172/JCI127721. View

19.

Basso K, Dalla-Favera R . Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015; 15(3):172-84. DOI: 10.1038/nri3814. View

20.

Calado D, Sasaki Y, Godinho S, Pellerin A, Kochert K, Sleckman B . The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol. 2012; 13(11):1092-100. PMC: 4132664. DOI: 10.1038/ni.2418. View